Artificial intelligence news.
Straight from the original announcements.

Hone Health raises $228M to expand AI-supported longevity care

November 18, 2026, 15:46By the AI News Bites Editorial TeamSource: PR Newswire
Hone Health raises $228M to expand AI-supported longevity care
Image: PR Newswire

Hone Health has raised $228M to expand its physician-led longevity platform, develop new clinical pathways and build AI-enabled tools that turn patient data into physician-directed care. The financing was led by MarcyPen Capital Partners and includes $28M in Series A equity financing and $200M in growth financing from General Catalyst's Customer Value Fund.

Key points
  • Hone Health raised $228M in financing led by MarcyPen Capital Partners.
  • The financing includes $28M in Series A equity and $200M in growth financing from General Catalyst's Customer Value Fund.
  • Hone plans to expand programs, diagnostics, peptide care and clinical trials.
  • Hone Black will offer more than 1,600 health markers and ongoing care from dedicated physicians.
  • Hone says it has treated more than 200,000 patients and processed 25 million health markers.

Funding will support broader clinical care

Hone Health said the investment will fund expansion across metabolic health, PMOS, inflammation and immunity. The company also plans to integrate additional diagnostic tools into longitudinal care, including full-body MRI, DEXA scans, coronary CT angiography and gut microbiome analysis.

The company described the goal as creating a more connected view of the factors influencing a patient's health. It also said it intends to build one of the most complete health datasets ever assembled.

Hone will use the financing to advance its clinical technology, bringing together lab results, health history, symptoms, medications and longitudinal outcomes. According to Hone, these tools will help physicians personalize and adapt care, while accelerating the development of technology that turns biomarkers into personalized treatment plans.

  • New physician-led programs in metabolic health, PMOS, inflammation and immunity
  • Additional diagnostic tools, including full-body MRI and DEXA scans
  • A physician-supervised peptide program for eligible patients where legally available and clinically appropriate
  • Expanded clinical trials infrastructure to study patient outcomes

Hone Black brings diagnostics and ongoing care together

Hone also plans to publicly launch Hone Black, its most comprehensive and personalized membership. The concierge longevity program has operated in stealth for the past year and served a select group of high-profile patients.

Hone Black combines more than 1,600 health markers with ongoing care from a dedicated team of physicians responsible for whole-body care. Treatment options include prescription medications, supplements, peptides and lifestyle guidance, as well as exosome and stem cell therapies, according to the company.

Hone said it has treated more than 200,000 patients, administered 750,000 tests and processed 25 million health markers. Its proprietary AI clinical platform, Longevity OS, gives physicians a real-time view of each patient's health across specialties. The company says that data feeds the platform and sharpens its clinical intelligence with every patient treated.

A larger role for data in preventive health

Hone co-founder and CEO Saad Alam said consumers have many options for preventive health but are seeking deeper insight into their health metrics. He said Hone combines diagnostic testing, physician-led care and AI-powered insights, and that the funding will help extend the company's approach into new therapeutic categories.

The financing follows Hone's $33 million Series A, announced in January 2025. That round supported the company's expansion beyond hormone health optimization into broader longevity care. Since then, Hone has launched a cardiovascular program using advanced health markers, along with integrated Prenuvo whole-body MRI and BodySpec DEXA scans.

The new capital gives Hone resources to connect more diagnostics, treatment options and research activity within an ongoing care model. For users, the company's stated direction means more physician-led programs and a broader set of tests and therapies. For the market, it illustrates how longevity companies are combining clinical services with large health datasets and AI tools, while keeping physicians responsible for directing care.

Hone HealthMarcyPen Capital PartnersGeneral CatalystCustomer Value Fundhealthcareinvestment and acquisitionsenterprise AI

Related news

MemorialCare uses rapid technology to spot hidden brain aneurysms
Products and toolsNovember 19, 2026, 20:46

MemorialCare uses rapid technology to spot hidden brain aneurysms

MemorialCare Neuroscience Institute is using rapid aneurysm technology to spot hidden brain aneurysms, according to a PR Newswire release. The announcement describes the…

Research
ResearchNovember 19, 2026, 15:00

Aidoc reports faster PE response and broader therapy use with AI workflows

AI-enabled pulmonary embolism workflows were linked to faster PERT activation, higher advanced therapy utilization and shorter hospital stays in research presented at…

Collective raises $100M to build an AI financial OS for solo businesses
BusinessOctober 29, 2026, 20:20

Collective raises $100M to build an AI financial OS for solo businesses

Collective, an AI-native financial operating system for one-person businesses, has raised $100 million in new funding. The round combines a $40 million Series B with a…